Proposition - PharmXpert Academy

474 2007 Korea Pharmaceutical Industry Directory
49. PHARMAKING
1. Company Information
Company
PHARMAKING
Representative Won-Bae, Kim E-mail tae129@pharmaking.co.kr
Representative
Phone No.
Hompage
Address
Research
Institute Address
Year of
Establishment
The Number of
Employees (06‘)
82-2-3497-5900
http://www.pharmaking.co.kr/
Representative
Fax No.
82-2-246-4125
3F Baek Sin B/D, 37-22, Samsung-dong, Gangnam-gu, Seoul, Korea
Factory: 826, Sinheung-dong, Sujeong-gu, Seongnam-si, Gyeonggi-do
1975 Sales (‘06) 14.4 Million$
Total
The Number of
120 Researcher (‘06) 7
Total
Contact Person Mi-Jin, Sun Contact Phone 82-2-3497-5942
Contact E-mail sunmj@pharmaking.co.kr Contact Fax 82-2-546-4125
Introduction of Company
Since its establishment in 1975 as Taerim Industry, the company name was changed to Taerim
Pharmaceutical in 1988. Since then, we became one of the leading R&D-oriented biotechnology
venture through its continuous efforts to develop unique medicines for the improvement of human
health and eradication of diseases. We are the industry leader in the field of hepatitis medicine.
After the introduction of the Substance Patent System in 1987, we realized that the future of
medicine manufacturers would depend on developing competitive medicines. We have been
investing more than 20% of its total sales into R&D for the development of new medicines. As
a result, the first hepatitis medicine in Korea named “Nissel” was developed in July 1990.
Furthermore, after obtaining a patent for a new hepatitis medicine and completing the phase Ⅲ
clinical trial, “Pennel” was launched in Feb. 1998. At the present, “Pennel” capsule is the most
popular drug against the hepatitis in Korea and its superiority has been widely recognized in
numerous Southeast Asian countries including Vietnam. Recently, Taerim started to export “Pennel”
to Egypt.
Through extensive experience in research and development, we strive to constantly develop
new drugs for the treatment against adult diseases using natural substances. For the first time in
the world, we obtained the patent on the hepatitis C drug and is actively preparing to
commercialize it.
Since our establishment, we have made every effort to improve the health of people around
the world. We will continue to exert our best to become a respectful company that thrives to make
the world without any diseases.